A detailed history of Transcend Capital Advisors, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Transcend Capital Advisors, LLC holds 1,382 shares of KRYS stock, worth $244,461. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,382
Holding current value
$244,461
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$174.7 - $213.66 $241,435 - $295,278
1,382 New
1,382 $251,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.54B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Transcend Capital Advisors, LLC Portfolio

Follow Transcend Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Transcend Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Transcend Capital Advisors, LLC with notifications on news.